The U.S. Senate Banking Committee will not have any markup hearings on market structure legislation defining how federal regulators can oversee the industry until next year, punting on a hoped-for ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

A thick layer of more than 12 miles of rock may explain why Bermuda seems to float above the surrounding ocean. When you purchase through links on our site, we may earn an affiliate commission. Here’s ...

After weeks of what had been tightly buttoned talks between the parties, Senate Democrats have delivered their latest counteroffer on the crypto market structure bill, outlining a set of demands ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

How is AI and data leadership at large organizations being transformed by the accelerating pace of AI adoption? Do these leaders’ mandates need to change? And should overseeing AI and data be viewed ...

COLUMBIA — A new Ameren Missouri rate structure for large load users aims to make advanced manufacturers and data centers pay their fair share — and the Missouri Public Service Commission approved the ...

With the federal government on the verge of reopening, the economic data drought caused by the shutdown may also soon come to an end. As the Bureau of Labor Statistics prepares to release weeks of ...

OpenAI announced Tuesday morning that it had completed a tumultuous corporate restructuring effort, simplifying a complex ownership web into a controlling nonprofit entity and a reimagined for-profit ...

Perhaps in the earlier days of AI/ML, you were a little curious about what the limiting factors would be in these new technologies. One potential one was cost, but we’ve seen the value of compute ...